Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment
2020
Dalbavancin
is a novel semi-synthetic glycopeptide antibiotic. In this study, we aimed to
optimize the dosage regimen of dalbavancin in patients with hepatic or renal
impairment by Mote
Carlo simulation. Pharmacokinetic parameters and microbiological data were
collected about dalbavancin. 10,000 patients with renal or hepatic impairment
analyzed by Crystal Ball to calculate probability of target attainment (PTA)
and cumulative fraction of response (CFR). We found that all bacterial PTA and CFR were more
than 90% for dalbavancin in patients with hepatic or renal impairment, except
for Enterococcus faecium. There is no need to adjust the dosage regimen of dalbavancin in
patients with hepatic or renal impairment.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI